WO2022149057 - CDK INHIBITORS
National phase entry is expected:
Publication Number
WO/2022/149057
Publication Date
14.07.2022
International Application No.
PCT/IB2022/050026
International Filing Date
03.01.2022
Title **
[English]
CDK INHIBITORS
[French]
INHIBITEURS DE CDK
Applicants **
RHIZEN PHARMACEUTICALS AG
INCOZEN THERAPEUTICS PVT. LTD.
Inventors
VAKKALANKA, Swaroop Kumar Venkata Satya
BHUNIYA, Debnath
VISWANADHA, Srikant
ELESWARAPU, Venkata Satyanarayana
Priority Data
202141000378
05.01.2021
IN
202141044661
01.10.2021
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4126 | |
| EPO | Filing, Examination, Granting | 24710 | |
| Japan | Filing, Examination, Granting | 2929 | |
| South Korea | Filing, Examination, Granting | 3852 | |
| USA | Filing, Examination, Granting | 12490 |
Total:
48,107
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof as cyclin-dependent kinase inhibitors (one or more of CDK1, CDK2, CDK4, and CDK6), methods of preparing them, and pharmaceutical compositions containing them. The compounds of the present invention are useful in the treatment, prevention and/or amelioration of diseases or disorders associated with one or more of CDK1, CDK2, CDK4, and CDK6.[French]
La présente invention concerne des composés de formule (I) et des sels pharmaceutiquement acceptables de ceux-ci en tant qu'inhibiteurs de kinase dépendant de la cycline (un ou plusieurs parmi CDK1, CDK2, CDK4 et CDK6), leurs procédés de préparation, et des compositions pharmaceutiques les contenant. Les composés de la présente invention sont utiles dans le traitement, la prévention et/ou le soulagement de maladies ou de troubles associés à un ou plusieurs parmi CDK1, CDK2, CDK4 et CDK6.